Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, proof-of-concept, Phase 2 trial evaluating safety and efficacy of Otlertuzumab in combination with bendamustine in patients with relapsed or refractory peripheral T-cell lymphomas (PTCL)

Trial Profile

An open-label, proof-of-concept, Phase 2 trial evaluating safety and efficacy of Otlertuzumab in combination with bendamustine in patients with relapsed or refractory peripheral T-cell lymphomas (PTCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Bendamustine (Primary) ; Otlertuzumab (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2018 According to an Aptevo Therapeutics financial report, results were presented.
    • 13 Mar 2018 According to an Aptevo Therapeutics media release, the company anticipates to report preliminary data in Q4 2018.
    • 08 Jan 2018 Status changed from planning to recruiting, according to an Aptevo Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top